Beyond scratching the surface




Download the Full Agenda

Not Only Spray-Drying – Particle Engineering in Dry Powder Inhaler (DPI) Formulations

Prof. Dr. Regina Scherließ, University of Kiel

Connecting Ps of dry powder inhalation (DPI) development: Particles, properties, processing, and performance

Dr. Amrit Paudel, Technical University Graz

Controlling Shape and Structure of Supraparticles by Tuning Colloidal Interactions

Dr. Michael Kappl, Max-Planck-Institute

How to Discriminate Dissolution Profiles of Engineered Powders

Dr. Francesca Buttini, University of Parma

Formulation and Production of Carrier-Free Powders for Dry Powder Inhalers (DPIs)

Prof. Dr. Anne Marie Healy, Trinity College Dublin

Advanced Lipid Excipients (Polyglyceryl-Ester) for Pulmonal Drug Delivery: Overcoming the Challenges of Conventional Formulations

Priv-Doz. Dr. Sharareh Salar-Behzadi, RCPE

Particle Engineering by Crystallization

Dr. Peter Neugebauer, Technical University Graz

Particle Engineering and Drug Delivery by Inhalation: Barriers and Opportunities to get to the market – An Industry Perspective

Dr. Alessandro Cavecchi, Chiesi Farmaceutici

Linking Particle Properties to Their Predicted In-Vivo Performance: An In-Vitro-In-Silico Case Study Using Different Lactose Grades

Dr. Joana Pinto, RCPE


Chiesi Farmaceutici

Alessandro Cavecchi

Head of Pharmaceutical Technology

Head of Pharmaceutical Technology Section at Chiesi Farmaceutici with a Magister degree in Industrial Chemistry from the University of Parma (IT), Alessandro has over 20 years of experience in the development of inhalation dosage forms. Specialized in Dry Powder Inhalers (DPIs) and pressurized Metered Dose Inhalers (pMDIs), in his current role he ensures scientifically sound and robust formulation and process development of all dosage forms in the Chiesi R&D pipeline for respiratory and special care areas. Prior to joining Chiesi, Alessandro worked for Zentiva (Sanofi Generics) as Senior Formulation Manager in charge of formulation and manufacturing development of generic inhalation products, and Novartis as formulation Fellow supporting the establishment of the Breezhaler® portfolio.
University of Kiel

Regina Scherließ

professor for Pharmaceutics and Biopharmaceutics, managing director of the section Pharmacy and chair of the Department of Pharmaceutics at Kiel University, Germany

Prof. Dr. Regina Scherließ (*1979) is a professor for Pharmaceutics and Biopharmaceutics, managing director of the section Pharmacy and chair of the Department of Pharmaceutics at Kiel University, Germany. As such she leads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics at Kiel University. She is a pharmacist and received her Dr. rer. nat. (doctor of natural sciences) in 2008 for a work on “Formulation of inhalation combination products by co-precipitation”. In 2015 she finished her “habilitation” working on “Mucosal vaccination via the respiratory tract”. During her academic education she had research stays in Denmark, the US, New Zealand and Australia. She also received several young researcher awards including The Pat Burnell New Investigator Award 2010 of the Aerosol Society and is member of the DDL scientific committee (since 2015). She also is member of the board of the research focus area KiNSIS (Kiel Nano Interface and Surface Sciences) at Kiel University. Her research interests include disperse systems and nanoparticles, stabilization of biomolecules and particle engineering in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery. She is a co-founder of the Nasal Research Focus Group, a research consortium from academia and industry focusing on nasal drug delivery.

My research interests include disperse systems and nanoparticles, stabilisation of biomolecules and particle engineering in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery. My work comprises formulation development and optimisation, functional characterisation as well as basic research exploring underlying principles in formulation and performance. Recent projects work on novel non-spherical dry powder carriers, softpellets and drug nanocrystals for high dose application of powders to the lung, mucosal vaccination via the respiratory tract, nose-to-brain delivery, the in vitro assessment of nasal excipients, the exploration of surface energy in powders for inhalation and the development of nanoparticulate drug carrier systems.

Max Planck Institute

Michael Kappl

Group Leader at the MPI for Polymer Research in Mainz

Michael Kappl studied physics from 1983-1990 at the University of Regensburg and the Technical University of Munich. From 1991 to 1996 he did his PhD thesis work in Prof. Ernst Bamberg's group at the Max-Planck-Institute of Biophysics in Frankfurt, on transport kinetics of the Na+-Ca2+exchanger membrane protein. From 1997 to 1998 he did one year of postdoctoral research at the University of Mainz in the group of Prof. Butt. From 1998 - 2000 he was working as a consultant for Windows network solutions at the Pallas Soft AG, Regensburg. He rejoined the group of Prof. Butt in August 2000 at the University of Siegen.

Since 2002 he is group leader at the MPI-P, working in the fields of surface forces, wetting and characterization of mechanical properties on the micro- and nanoscale. In addition he is heading the Focused Ion Beam Service Lab, providing service for nanostructuring, cross-sectioning of samples, preparation of TEM lamella, and 3D tomography.

His research is focused on surface forces and mechanics on nano- and microscale and wetting.

Trinity College Dublin

Anne Marie Healy

Professor of Pharmaceutics and Pharmaceutical Technology

Anne Marie Healy is Professor of Pharmaceutics and Pharmaceutical Technology in the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Ireland. Anne Marie has a B.Sc. in Pharmacy and a Ph.D. in Pharmaceutics, both from the University of Dublin. She joined the School of Pharmacy, TCD in 1992 as a Lecturer in Pharmaceutics. In 2010 she was elected Fellow of Trinity College.

Professor Healy has published extensively, with over 110 international peer reviewed publications. She has graduated 21 PhD students, mentored 26 postdoctoral researchers, and has been awarded €10 million in competitive grant income.
Her research interests include pharmaceutical material science, preformulation and formulation of pharmaceuticals, amorphous solids, co-crystals, formulating poorly soluble drugs, pharmaceutical processing and pulmonary drug delivery.

Anne Marie is a Co-Principal Investigator of the SSPC - the Science Foundation Ireland Research Centre for Pharmaceuticals ( and is one of the Co-Directors of the EPSRC-SFI Centre for Doctoral Training in Transformative Pharmaceutical Technologies (


Johannes Khinast

Head of the Institute for Process and Particle Engineering at Graz University of Technology and Scientific Director of RCPE

Prof. Johannes G. Khinast is the head of the Institute for Process and Particle Engineering ( at the Graz University of Technology and the scientific director of the Research Center Pharmaceutical Engineering (

He received his Ph.D. in the area of particle technology in 1995 from the Graz University of Technology in 1995. He was then a post doctoral fellow at the University of Houston with Prof. Dan Luss. In 1998 Prof. Khinast joined Rutgers University (New Jersey, USA) as an assistant professor, where he was granted early tenure in 2003. During his period at Rutgers University Prof. Khinast received several important awards, including the Bristol-Myers Squibb Young Faculty Development Award (1999), the DuPont Young Professor Award (2000), the North American Mixing Forum Award (2000) and finally in 2001 the prestigious NSF CAREER Award. In 2005 Prof. Khinast was selected as a Marie Curie Chair of the EU, and in 2006 he was offered a professorship at the Graz University of Technology. Prof. Khinast has received significant funding for his work in process simulation, pharmaceutical process engineering and particle technology in the order of more than 80 million Euros from various sources.

He also has worked with a large number of pharmaceutical and equipment companies and serves an advisor for the implementation of novel technology. He has supervised more than 40 Ph.D. students and PostDocs and his publication record encompasses over 300 peer-reviewed publications and 8 book chapters. He also holds 11 patents in the area of pharmaceutical manufacturing.

IOI Oleo GmbH

Dieter Scherer

IOI Oleo Senior Advisor Pharma

Pharmacist (Apotheker), Ph.D. in Pharmaceutics specialized in Drug Delivery of poorly soluble drugs. Professional expertise in business and science related to drug product devel-opment in start-ups, medium and global companies including own entrepreneurial experience. In depth experience with pharmaceutical excipients in particular polysorb-ates, synthesis and characterization. Since 2018 Expert Advisor for the United States Pharmacopeia (USP). Specialised in the product development of innovative drug formulations, of a variety of dosage forms, (oral, topical, ophthalmic, transdermal). Developed three products that are on the market EvoTears, EvoTears Omega and Solaraze. In addition two innovative products are in PH III in the USA. I transferred several products from lab stage to CMOs until market launch. In addition, I have relevant regulatory experience. I served as "Informationsbeauftragter" and deputy "Stufenplanbeauftragter". I hold the "Sachkundenachweis", according to §15 (German) AMG, qualifies for QP.

I co-authored 15 patent families.
Throughout my career, I licensed successfully technologies and products including nanotechnologies for poorly soluble drugs. As member of the leadership team, I was jointly responsible for four financing rounds. In addition, I served 4 years as board member at Novaliq.
In 2003, I was founder of APISPHARMA AG, a consulting firm, covering the whole value chain from idea to market, including licensing, IP and business development in the biomedical industry for innovative dosage forms, mainly active in the start-up environment.
From 2003 until 2016 I worked in the start-up environment in a variety of func-tions.
In 2013, I became CSO at Novaliq after serving 4 years as Board Member and Head of Business Development. In this function I developed the core of Novaliq IP, 10 patent families, developed a novel drug delivery technology for eye drops from concept to market launch (EvoTears
As from 2016, I started at Lonza as Senior Advisor and subsequently becoming Head Application Development Excipients in 2017, responsible for the devel-opment of an improved generation of pharmaceutical excipients, leading to 3 patent families (not published yet).
I have worked within international teams and in different cultural environments for companies throughout Europe, including Germany, Switzerland, Denmark, and Sweden. This led to an extensive network both, in industry and academia.

I am an open minded, curious and innovative personality with a high grade of dedi-cation and result orientation combined with business sense and strength for identi-fying out of the box solutions.

University of Parma

Francesca Buttini

Associate Professor at the Department of Pharmacy, University of Parma

Francesca Buttini is currently holding an Associate Professor position at the Department of Pharmacy, University of Parma (IT) where she got the PhD title in 2004 and where now she is leading the unit dedicated to design of pharmaceutical products for inhalation. In 2014, she was appointed as Visiting Lecturer at the Institute of Pharmaceutical Science of King’s College London (UK). In 2016 she has been affiliated as Key Researcher at the Research Center Pharmaceutical Engineering (Austria).

Combining her background in pharmaceutical technology, regulatory aspects and device construction, she is leading and executing research programs aimed to deliver medicinal products that take into consideration the patient, industrial and regulatory requirements. As a result of her research achievement she obtained in 2017 the DDL Emerging Scientist Awards from the UK Aerosol Society.

Francesca Buttini is a founder of PlumeStars, an innovative SME, dedicated to development of orphan drug products to treat lung and systemic disease by inhalation therapy.



Tickets are refundable up to 30 days before the event starts


However, particle engineering has moved beyond simple particle size control. New technologies and innovative approaches have led to a revolution in the field. This workshop is dedicated to these developments. Researchers will present their most recent innovations, including novel excipients for pharmaceutical applications, particle characterizations, and simulative approaches. Innovations that allow us to break new grounds in drug delivery, such as inhalation, and maximize the therapeutic potential of a diverse range of particles.

Welcome to the most particle-centric workshop on earth.



Sometimes a brief moment is all it takes, and 3 minutes are all you get.

For the first time, we will be hosting a pitch competition for emerging scientists currently enrolled in a Ph.D. Degree Programme. Show us that your work will change how we design and engineer particles in the future. Blow us away with a presentation that is just on point and leaves us demanding more, and walk away with the grand prize after being judged by a jury of your peers.

All you need to do is simply submit a one-page abstract describing your work using the official template. We will evaluate your work and select 7 lucky contestants for the live session in Graz.

Extended Submission Deadline: August 15 2022

Download Abstract Template

Evaluation Committee:
Prof. Dr. Johannes Khinast – CEO & Scientific Director RCPE

Prof. Dr. Eva Roblegg – University of Graz
Assoc. Prof. Dr. Francesca Buttini – University of Parma
Dr. Sarah Neugebauer – Senior Scientist RCPE




    The workshop is about connections. We connect theory and practice, researchers with industrial counterparts, and most importantly, problem solvers with solution seekers. This workshop is part of the international Galenus Workshop Series and receives additional funding by RCPE.

    LAST UPDATED: MARCH 30, 2022


    The safety and protection of participants is of the utmost importance. We will follow health and safety measures issued at the time of the events by federal and local authorities. Before the workshop you will receive additional information on enforced risk mitigation measures.

    Limited Event Capacity

    Attendance in all events areas will be limited as per venue requirements.

    Personal Protective Equipment

    Face coverings will be provided for all attendees, and guests. Hand sanitizing products will be made available throughout the event space.

    Entry into Austria and Pre-Travel Clearance

    For information on possible entry regulations and needed verification, please refer to the official website of the Austrian government.


    These measures will be adjusted based on changes to state and local requirement. For more information, refer to this overview on the coronavirus situtation in Austria.


    We are pleased to answer any questions you may have about the workshop and we will respond to your requests immediately.

    Dr. Sarah Neugebauer
    Senior Scientist

    T +43 316 873 30945

    Constantin Schmidt, BA MA MA
    Head of Marketing & PR

    T +43 316 873 35915